FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the ...
VERTANICAL today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, the company's ...
Chronic neuropathic pain remains one of the most challenging conditions to treat, with current therapies offering limited ...
“A little blue pill is creating a stir in Hollywood,” said Dipa Kamdar, senior lecturer in pharmacy practice at Kingston University, London, on The Conversation. “And no, it’s not Viagra.” For several ...
While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
Key Regulatory Benchmark Met, Differentiating DMX-101 from Traditional Opioid AnalgesicsLate-Breaking Results to be Presented ...
A local chiropractor discussed non-medication treatment options for peripheral neuropathy, a condition affecting more than 20 ...
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50 ...
Pacira’s board urges stockholders to realize that their investments would be put at serious risk in the event of any of ...
Pharmaceutical Technology on MSN
Partner Therapeutics secures FDA approval for Bizengri
The FDA approval was based on data from the multi-centre, open-label Phase II eNRGy clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results